Skip to main content

Table 2 Univariate analysis of prognostic factors affecting RFI, OS 1 , PFS and OS 2

From: The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Factors Median RFI (months) Pvalue* Median OS1(months) Pvalue* Median PFS (months) Pvalue* Median OS2(months) Pvalue*
Age         
 ≤ 50 NA†   NA†   10.0 0.868 36.5 0.966
 > 50    10.9   NR  
Menstruation status         
 Pre-menopausal NA†   NA†   9.5 0.985 36.5 0.565
 Post-menopausal    11.3   NR  
Histology         
 IDC 31.5 0.550 130.8 0.454 10.4 0.513 36.5 0.560
 ILC 36.4   NR   4.4   NR  
 Others 39.1   72.8   17.2   32.6  
Luminal subtype         
 Luminal A 41.2 <0.001 222.1 0.011 11.6 0.550 36.5 0.233
 Luminal B 24.2   71.7   9.4   32.6  
Adjuvant/neoadjuvant therapy         
 Only CT (± RT) 17.7 0.138 NR 0.927 5.1 0.463 NR 0.639
 Only HT (± RT) 17.2   NR   23.2   NR  
 CT + HT (± RT) 36.1   NR   11.3   NR  
 Therapy with TT 28.9   NR   8.4   NR  
 No 28.9   NR   13.7   NR  
Relapse-free interval         
 ≤ 2 years NA   NA   8.2 0.003 22.8 0.017
 > 2 years    12.9   NR  
No. of metastatic sites         
 1 NA   NA   13.0 0.002 NR 0.032
 2    16.5   32.6  
 ≥ 3    8.4   25.1  
Visceral metastasis         
 Yes NA   NA   9.0 0.035 36.5 0.393
 No    13.3   NR  
First-line therapy after PET/CT       
 HT NA   NA   21.0 0.037 NR 0.019
 CT (± TT)    9.5   32.6  
Baseline SUVmax         
 ≤ 5.60 (Lowest tertile) NA   NA   19.2 0.002 NR 0.009
 5.60 ~ 8.70 (Intermediate tertile)    10.4   35.3  
 > 8.70 (Highest tertile)    8.2   22.6  
  1. RFI: relapse-free interval; OS: overall survival; PFS: progression-free survival; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; CT: chemotherapy; RT: radiotherapy; HT: hormonal therapy; TT: target therapy; No.: number; SUVmax: the maximum standardized uptake value; NA: not applicable; NR: not reached.
  2. * Log-rank test.
  3. † The data of age and menstruation status were collected after diagnosis of relapse and informed consent obtained. These data were different from those at diagnosis of primary breast cancer.